Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA. |  |
|
|
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Singhal Priya | Head of Development | Feb 10 '25 | Option Exercise | 0.00 | 1,212 | 0 | 9,423 | Feb 12 05:48 PM | Murphy Nicole | Head of Pharm Ops and Tech | Feb 10 '25 | Option Exercise | 0.00 | 2,272 | 0 | 14,725 | Feb 12 05:47 PM | MCDONNELL MICHAEL R | EVP, Chief Financial Officer | Feb 10 '25 | Option Exercise | 0.00 | 3,257 | 0 | 25,712 | Feb 12 05:46 PM | Kramer Robin | Chief Accounting Officer | Feb 10 '25 | Option Exercise | 0.00 | 834 | 0 | 8,257 | Feb 12 05:44 PM | Gregory Ginger | EVP, Human Resources | Feb 10 '25 | Option Exercise | 0.00 | 2,159 | 0 | 18,232 | Feb 12 05:43 PM | ALEXANDER SUSAN H | EVP Chief Legal Officer | Feb 10 '25 | Option Exercise | 0.00 | 2,575 | 0 | 37,072 | Feb 12 05:42 PM | Izzar Rachid | Head of Global Product Strat. | Feb 10 '25 | Option Exercise | 0.00 | 1,515 | 0 | 8,998 | Feb 12 05:40 PM | Izzar Rachid | Head of Global Product Strat. | Feb 07 '25 | Option Exercise | 0.00 | 3,844 | 0 | 7,860 | Feb 11 09:52 PM | MCDONNELL MICHAEL R | EVP, Chief Financial Officer | Feb 07 '25 | Option Exercise | 0.00 | 4,551 | 0 | 23,171 | Feb 10 06:59 PM | Viehbacher Christopher | President and CEO | Feb 07 '25 | Option Exercise | 0.00 | 9,008 | 0 | 16,008 | Feb 10 06:55 PM | Grogan Jane | Head of Research | Feb 07 '25 | Option Exercise | 0.00 | 1,385 | 0 | 1,876 | Feb 10 06:52 PM | Keeney Adam | Head of Corporate Development | Feb 07 '25 | Option Exercise | 0.00 | 1,801 | 0 | 2,463 | Feb 10 06:51 PM | Kramer Robin | Chief Accounting Officer | Feb 07 '25 | Option Exercise | 0.00 | 1,491 | 0 | 7,667 | Feb 10 06:48 PM | Murphy Nicole | Head of Pharm Ops and Tech | Feb 07 '25 | Option Exercise | 0.00 | 4,042 | 0 | 13,056 | Feb 10 06:47 PM | Singhal Priya | Head of Development | Feb 07 '25 | Option Exercise | 0.00 | 2,216 | 0 | 8,892 | Feb 10 06:45 PM | Gregory Ginger | EVP, Human Resources | Feb 07 '25 | Option Exercise | 0.00 | 3,436 | 0 | 16,633 | Feb 10 06:44 PM | ALEXANDER SUSAN H | EVP Chief Legal Officer | Feb 07 '25 | Option Exercise | 0.00 | 4,130 | 0 | 35,088 | Feb 10 06:42 PM | Singhal Priya | Head of Development | Jan 31 '25 | Option Exercise | 0.00 | 1,828 | 0 | 7,254 | Feb 03 06:02 PM | Singhal Priya | Head of Development | Dec 06 '24 | Option Exercise | 0.00 | 426 | 0 | 5,742 | Dec 09 04:57 PM | Singhal Priya | Head of Development | Dec 09 '24 | Sale | 157.21 | 110 | 17,293 | 5,426 | Dec 09 04:57 PM | Kramer Robin | Chief Accounting Officer | Dec 06 '24 | Option Exercise | 0.00 | 351 | 0 | 6,578 | Dec 09 04:56 PM | Singhal Priya | Officer | Dec 09 '24 | Proposed Sale | 157.21 | 110 | 17,293 | | Dec 09 10:33 AM | Grogan Jane | Head of Research | Nov 01 '24 | Option Exercise | 0.00 | 695 | 0 | 695 | Nov 04 04:39 PM | Singhal Priya | Head of Development | Aug 30 '24 | Option Exercise | 0.00 | 1,668 | 0 | 6,554 | Sep 05 06:00 AM | Singhal Priya | Head of Development | Sep 03 '24 | Sale | 204.22 | 431 | 88,019 | 5,316 | Sep 05 06:00 AM | Singhal Priya | Officer | Sep 03 '24 | Proposed Sale | 204.22 | 431 | 88,019 | | Sep 03 01:00 PM | Keeney Adam | Head of Corporate Development | May 01 '24 | Option Exercise | 0.00 | 938 | 0 | 938 | May 03 08:00 PM | Singhal Priya | Head of Development | Apr 02 '24 | Sale | 213.09 | 93 | 19,817 | 4,886 | Apr 03 08:24 PM | Murphy Nicole | Head of Pharm Ops and Tech | Apr 01 '24 | Option Exercise | 0.00 | 240 | 0 | 9,751 | Apr 03 08:11 PM | Singhal Priya | Head of Development | Feb 22 '24 | Sale | 221.23 | 262 | 57,962 | 4,886 | Feb 26 07:54 PM | ALEXANDER SUSAN H | EVP Chief Legal Officer | Feb 16 '24 | Option Exercise | 0.00 | 5,037 | 0 | 52,506 | Feb 21 09:39 PM | Gregory Ginger | EVP, Human Resources | Feb 16 '24 | Option Exercise | 0.00 | 4,704 | 0 | 14,341 | Feb 21 09:36 PM | Izzar Rachid | Head of Global Product Strat. | Feb 16 '24 | Option Exercise | 0.00 | 2,017 | 0 | 10,014 | Feb 21 09:33 PM | Kramer Robin | Chief Accounting Officer | Feb 16 '24 | Option Exercise | 0.00 | 1,345 | 0 | 6,354 | Feb 21 09:31 PM | MCDONNELL MICHAEL R | EVP, Chief Financial Officer | Feb 16 '24 | Option Exercise | 0.00 | 6,720 | 0 | 20,692 | Feb 21 09:29 PM | Murphy Nicole | Head of Pharm Ops and Tech | Feb 16 '24 | Option Exercise | 0.00 | 1,260 | 0 | 9,624 | Feb 21 09:28 PM | Singhal Priya | Head of Development | Feb 16 '24 | Option Exercise | 0.00 | 1,208 | 0 | 5,429 | Feb 21 09:27 PM | Singhal Priya | Head of Development | Feb 16 '24 | Sale | 221.49 | 108 | 23,921 | 5,148 | Feb 21 09:27 PM | Rowinsky Eric K | Director | Feb 15 '24 | Buy | 222.54 | 455 | 101,256 | 20,629 | Feb 20 09:13 PM |
|